Welcome to our dedicated page for Delcath Systems news (Ticker: DCTH), a resource for investors and traders seeking the latest updates and insights on Delcath Systems stock.
Delcath Systems Inc. (Nasdaq: DCTH) is a prominent interventional oncology company focusing on the treatment of primary and metastatic liver cancers. The company's flagship product, the HEPZATO KIT™ (comprising Hepzato (melphalan) for Injection and the Hepatic Delivery System), offers a revolutionary approach to liver-directed chemotherapy. This system enables high-dose chemotherapy delivery directly to the liver, minimizing systemic exposure and associated side effects.
HEPZATO KIT is FDA-approved in the United States for treating adult patients with metastatic uveal melanoma (mUM) presenting unresectable hepatic metastases, especially when the metastases affect less than 50% of the liver and there is no extrahepatic disease, or extrahepatic disease limited to specific regions like bone or lymph nodes that can be managed surgically or through radiation. The product's approval followed the pivotal Phase 3 FOCUS study, which demonstrated a significant improvement in overall response rates and progression-free survival compared to historical data.
In Europe and the United Kingdom, Delcath markets the product under the trade name CHEMOSAT® Hepatic Delivery System for Melphalan. This device-only configuration has been utilized in over 250 treatments across 20 leading European cancer centers, establishing itself as a reliable option for liver cancer therapy.
Delcath continues to make strides in enhancing treatment accessibility. Recently, the company launched a Healthcare Setting Locator on their website to help patients, caregivers, and healthcare providers find facilities offering HEPZATO KIT treatment. The company also secured a permanent J-code for HEPZATO, streamlining the reimbursement process and facilitating broader patient access.
Recent business highlights include the first commercial use of HEPZATO KIT at Moffitt Cancer Center and the successful closing of a $7 million private placement to support ongoing commercial endeavors. Delcath has also published significant data from the FOCUS study in the Annals of Surgical Oncology, reinforcing the clinical efficacy of their treatment.
As Delcath Systems Inc. forges ahead, they remain committed to expanding the clinical adoption of their innovative therapies in major markets, thus providing critical treatment options to liver cancer patients worldwide.
Delcath Systems, Inc. (NASDAQ: DCTH) has resubmitted a New Drug Application (NDA) to the FDA for the HEPZATO™ Kit, aimed at treating unresectable hepatic-dominant metastatic ocular melanoma (mOM). This action addresses the issues raised in a Complete Response Letter from September 2013. A decision from the FDA is anticipated within 30 days. The NDA includes data from the FOCUS trial, showing a 36.3% overall response rate and a median overall survival of 20.53 months among treated patients. The HEPZATO Kit employs a unique delivery system designed to minimize systemic exposure to the drug while effectively targeting liver tumors.
Delcath Systems, Inc. (NASDAQ: DCTH) is set to participate in the BTIG MedTech, Digital Health, Life Sciences, & Diagnostics Tools Conference from February 14 to 16, 2023, in Snowbird, Utah. CEO Gerard Michel will hold one-on-one meetings during the event. The company specializes in treating primary and metastatic liver cancers, utilizing its percutaneous hepatic perfusion (PHP) system to deliver high-dose chemotherapy while minimizing side effects. In the U.S., the PHP system is under development as HEPZATO™ KIT for metastatic ocular melanoma, while in Europe, it's marketed as CHEMOSAT.
Delcath Systems, Inc. (DCTH) has published updated results from the Phase 1b CHOPIN Trial for treating advanced uveal melanoma with a combination of Delcath's CHEMOSAT and immune checkpoint inhibitors ipilimumab and nivolumab. The study, conducted at Leiden University Medical Center, showed a median progression-free survival (PFS) of 29.1 months, with all seven patients still alive at follow-up. The trial has demonstrated an 85.7% objective response rate and a 100% disease control rate. The ongoing Phase 2 part of the trial aims to further validate these findings with 76 additional patients enrolled.
Delcath Systems, Inc. (Nasdaq: DCTH) announced the granting of an equity award as an inducement for employment to an individual. The award consists of 12,500 shares of common stock outside its 2020 Stock Incentive Plan, with an exercise price equal to the closing stock price on the grant date. A third of the options will vest after one year, with the remainder vesting monthly over two years. This action complies with NASDAQ Listing Rule 5635(c)(4). Delcath specializes in interventional oncology for liver cancers, notably using the PHP system for treating unresectable hepatic-dominant metastatic ocular melanoma.
Delcath Systems, Inc. (Nasdaq: DCTH) has successfully closed a private placement, raising approximately $6.2 million. The placement involved issuing 1,448,889 shares of common stock at $2.90 per share, and 692,042 pre-funded warrants at $2.89, with an exercise price of $0.01. Proceeds will be used for working capital and corporate purposes. The securities sold are unregistered and Delcath plans to file for registration with the SEC. The company is focused on treating liver cancers via its proprietary PHP system, known as HEPZATO in the U.S. and CHEMOSAT in Europe.
Delcath Systems, Inc. (Nasdaq: DCTH) has announced a private placement transaction, raising approximately $6.2 million. The company will issue 1,448,889 shares of common stock at $2.90 per share, or 692,042 pre-funded warrants at $2.89 each. The proceeds will support working capital and other corporate needs. The issuance is not registered under the Securities Act and is subject to customary closing conditions. Delcath specializes in treating liver cancers with its proprietary PHP system, marketed as HEPZATO in the U.S. and CHEMOSAT in Europe.
Delcath Systems announces findings from a study showing that CHEMOSAT is a promising treatment for patients with advanced cholangiocarcinoma (CCA). Conducted on 17 patients, the study revealed a 25% overall response rate and a 75% disease control rate after 42 PHP procedures. The median survival post-treatment was 9.9 months, significantly longer than traditional options. While treatment presented minor and manageable side effects, the results affirm PHP’s potential in extending life for inoperable cases, making it a valuable palliative option.
Delcath Systems (Nasdaq: DCTH) announced the granting of equity awards as an inducement for employment to two individuals. A total of 40,000 shares of common stock were issued, with an exercise price based on the closing stock price on the grant date. The vesting schedule includes one-third of the options vesting on the first anniversary, followed by equal monthly installments over 24 months. These awards comply with NASDAQ Listing Rule 5635(c)(4) and were made per the company's amended stock incentive plan.
Delcath Systems, Inc. (DCTH) reported its third-quarter results on November 8, 2022, showing a total revenue of approximately $0.9 million, up from $0.5 million year-over-year, attributed to direct sales of CHEMOSAT in Europe. R&D expenses rose to $4.0 million from $3.0 million, driven by NDA filing preparations. The net loss increased to $8.5 million, or $0.92 per share, compared to $7.1 million, or $0.94 per share, in the previous year. The company raised $5 million through private placement, strengthening its balance sheet amidst ongoing developments for the Hepzato Kit NDA resubmission by year-end.
Delcath Systems, Inc. (Nasdaq: DCTH), specializing in interventional oncology, will host a conference call on November 8, 2022, at 8:30 AM ET to discuss its third quarter results for the period ending September 30, 2022. The conference will explore the company's proprietary percutaneous hepatic perfusion (PHP) system, designed for administering high-dose chemotherapy to liver cancers. Participants can dial in or join via a webcast link provided in the announcement. A replay will be available until November 15, 2022.
FAQ
What is the current stock price of Delcath Systems (DCTH)?
What is the market cap of Delcath Systems (DCTH)?
What is the primary focus of Delcath Systems Inc.?
What is the HEPZATO KIT?
Where is the HEPZATO KIT approved for use?
What is the CHEMOSAT® Hepatic Delivery System?
How many CHEMOSAT treatments have been performed in Europe?
What recent milestones has Delcath Systems Inc. achieved?
What was the outcome of the pivotal Phase 3 FOCUS study?
What support does Delcath offer for patients seeking HEPZATO KIT treatment?
How does the HEPZATO KIT minimize systemic exposure?
How does Delcath Systems Inc. support its commercial strategy in Europe?
